The flavonoid ampelopsin inhibited cell growth and induced apoptosis and G0/G1 arrest in human osteosarcoma MG-63 cells in vitro.
Ampelopsin (AMP), a novel flavonoid, has been shown to effectively inhibit the proliferation and induce apoptosis of some prostate cancer and breast cancer cell lines. Whether AMP has chemopreventive effects on the cell growth and apoptosis of human osteosarcoma MG-63 cells remains unknown. In the present study, MG-63 cells were exposed to different concentrations (0, 25, 50, 75, 100 μmol/L) of AMP for 24, 48, 72 and 96 h and then the cell viability was measured by CCK-8 assay. The AMP-induced apoptotic cells were identified by Hochest33258 staining and quantified by Annexin V-FITC/PI double staining using flowcytometry (FCM). The effect of ampelopsin (AMP) on cell cycle was evaluated using PI staining with FCM. The protein levels of cyclin A, CDK2 and p21(CIP1) were measured by Western blotting. The cell viability was reduced in a time- and dose-dependent manner after exposure to AMP atarangeof 20-100 μmol/L. For the treatment of AMP, increases of apoptotic index and rate were observed in MG-63 cells. The AMP blocked cells in the G0/G1 phase of the cell cycle. Furthermore, AMP increased p21(CIP1) expression but decreased cyclin A and CDK2 expression after AMP exposure. AMP inhibited cell growth and induced apoptosis and G0/G1 phase arrest in MG-63 cells in vitro, with the potential mechanism of the negative regulation of cell cycle-related protein.